CLIMB BIO, INC.

CLYM ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020
Operating Activities
Net Income $-59.9M $-73.9M $-35.1M $-45.2M $-47.5M $-20.7M
Depreciation & Amortization $97.0K $0
Depreciation
Amortization
Stock-Based Compensation $8.1M $5.6M $12.8M $7.0M $3.7M $707.0K
Net Cash from Operating Activities $-54.4M $-15.6M $-20.6M $-37.4M $-36.1M $-14.1M
Investing Activities
Capital Expenditures $186.0K $0 $0
Business Acquisitions $0 $4.6M
Net Cash from Investing Activities $2.8M $-121.1M $69.0M $34.4M $-115.0M $8.1M
Financing Activities
Dividends Paid
Stock Repurchases
Net Cash from Financing Activities $-21.0K $130.7M $841.0K $0 $177.2M $4.9M
Net Change in Cash $-51.5M $-5.9M $49.5M $-3.3M $26.4M $-736.0K
Free Cash Flow $-54.5M $-15.6M $-20.6M